Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2003-05-19
2010-11-09
Kam, Chih-Min (Department: 1656)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C530S300000, C530S391700, C530S370000, C530S396000, C530S403000, C514S002600, C514S012200, C435S069100, C435S252300, C435S320100, C424S183100, C536S023100
Reexamination Certificate
active
07829668
ABSTRACT:
The present invention provides methods to produce immunotoxins (ITs) and cytokines with a reduced ability to promote vascular leak syndrome (VLS). The invention also provides ITs and cytokines which have been mutated to lack amino acid sequences which induce VLS. Also disclosed are methods for producing peptides that inhibit the induction of VLS by ITs and cytokines. Also disclosed are peptides comprising the (x)D(y) sequence to promote the extravasation of other molecules. Toxins mutated in the (x)D(y) motif or active site residues are disclosed for used in vaccines.
REFERENCES:
patent: 4366241 (1982-12-01), Tom et al.
patent: 4435386 (1984-03-01), Ribi et al.
patent: 4436727 (1984-03-01), Ribi
patent: 4436728 (1984-03-01), Ribi
patent: 4866034 (1989-09-01), Ribi
patent: 4950645 (1990-08-01), Vosika et al.
patent: 4950740 (1990-08-01), Greenfield et al.
patent: 6566500 (2003-05-01), Vitetta et al.
patent: WO 91/16347 (1991-10-01), None
patent: WO 93/15113 (1993-08-01), None
patent: WO 94/13316 (1994-06-01), None
patent: WO 98/18820 (1998-05-01), None
patent: WO 99/60128 (1999-11-01), None
Negre et al. , J. Bol. Chem. 269, 22039-22045 (1994)).
Berndt et al. , Biochemistry 33, 6571-6577 (1994).
Morris et al.,Proc. Natl. Acad. Sci. USA 89, 4869-4873 (Jun. 1992).
Lu et al., J. Biol. Chem. 271, 289-294 (1996).
Baluna and Vitetta, “An in vivo model to study immunotoxin-induced vascular leak in human tissue,”J. Immunother., 22:41-47, 1999.
Baluna and Vitetta, “Vascular leak syndrome: A side effect of immunotherapy,”Immunopharmacology, 37:117-132, 1996.
Baluna et al., “Fibronectin inhibits the cytotoxic effect of ricin A chain on endothelial cells,”Int. J. Immunopharm., 18:355-361, 1996.
Coulson et al., “Rotavirus contains integrin ligand sequences and a disintegrin-like domain that are implicated in virus entry into cells,”Proc. Natl. Acad. Sci. U.S.A, 94:5389-5394, 1997.
Downie et al., “Interleukin-2 directly increases albumin permeability of bovine and human vascular endothelium in vitro,”Am. J. Respir. Cell Molec. Biol., 7:58-65, 1992.
Dutcher et al., “A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma,”J. Clin. Oncol., 9:641-648, 1991.
Engert et al., “The emerging role of ricin A-chain immunotoxins in leukemia and lymphoma,”In: Clinical Applications of Immunotoxins, Frankel (ed.), 2:13-33, 1997.
Ghetie et al., “The GLP large scale preparation of immunotoxins containing deglycosylated ricin A chain and a hindered disulfide bond,”J. Immunol Methods, 142:223-230, 1991.
Halling et al., “Genomic cloning and characterization of a ricin gene fromRicinus communis,” Nucleic Acids Res. 13:8019-8033, 1985.
Lamb et al., “Nucleotide sequence of cloned cDNA coding for preproricin,”Eur J Biochem, 148:265-270, 1985.
Mlsna et al., “Structure of recombinant ricin A chain at 2.3 Å,”Protein Sci., 2:429-435, 1993.
Munishkin and Wool, “Systematic deletion analysis of ricin A-chain function,”J. Biol. Chem., 270:30581-30587, 1995.
O'Hare et al., “Expression of ricin A chain inEscherichia coli,” Febs Lett., 216:73-78, 1987.
Orucevic and Lala, “NG-nitro-l-arginine methyl ester, an inhibitor of nitric oxide synthesis, ameliorates interleukin-2-induced capillary leak syndrome in healthy mice,”J. Immunother., 18:210-220, 1995.
Sausville and Vitetta, “Clinical studies with deglycosylated ricin a-chain immunotoxins,”In: Monoclonal Antibody-Based Therapy of Cancer, Grossbard (ed.), 4:81-89, 1997.
Soler-Rodriguez et al., “Ricin A-chain and ricin A-chain immunotoxins rapidly damage human endothelial cells: implications for vascular leak syndrome,”Exp. Cell Res., 206:227-234, 1993.
Soler-Rodriguez et al., The toxicity of chemically deglycosylated ricin a-chain in mice,Int. J. Immunopharm., 14:281-291, 1992.
Takada et al., “Molecular and structural requirements of a lipoteichoic acid fromEnterococcus hiraeATCC 9790 for cytokine-inducing, antitumor, and antigenic activities,”Infect Immun. 63:57-65, 1995.
Tselepis et al., An RGD to LDV motif conversion within the disintegrin kistrin generates an integrin antagonist that retains potency but exhibits altered receptor specificity,J. Biol. Chem., 272:21341-21348, 1997.
Vial and Descotes, “Clinical toxicity of interleukin-2,”Drug Safety, 7:417-433, 1992.
Baluna et al., “Evidence for a structure motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome,”PNAS USA, 96(7):3957-3962, 1999.
Baluna at al., “The effect of a monoclonal antibody coupled to ricin A chain-derived peptides on endothelial cells in vitro: insights into toxin-mediated vascular damage,”Exper. Cell Res., 258(2):417-424, 2000.
Day et al., “Structure and activity of an active site substitution of ricin A chain,”Biochem., 35(34):11098-11103, 1996.
Jackson et al., “Mutational analysis of the Shiga toxin and Shiga-like toxin II enzymatic subunits,”J. Bacteriology, 172(6):3346-3350, 1990.
Jackson et al., “Potent α4β1peptide antagonists as potential anti-inflammatory agents,”J. Med. Chem., 40(21):3359-3368, 1997.
Jia et al., “Function of disintegrin-like/cysteine-rich domains of atrolysin A: inhibition of platelet aggregation by recombinant protein and peptide antagonists,”J. Biol. Chem., 272(20):13094-13102, 1997.
Kagawa et al., “Crystal structure of the zymogen form of the group AStreptococcusvirulence factor SpeB: an integrin-binding cysteine protease,”PNAS USA, 97(5):258(2):2235-2240, 2000.
Stockbauer et al., “A natural variant of the cysteine protease virulence factor of group AStreptoccoccuswith an arginine-glycine-aspartic acid (RGD) motif preferentially binds human integrins αvβ3and αIIbβ3,”PNAS USA, 96(1):242-247, 1999.
Vitetta et al., “Immunotoxins: magic bullets or misguided missiles?,”Immunology Today, 14(6):252-259, 1993.
Frankel et al., “Role of arginine 180 and glutamic acid 177 of ricin toxin A chain in enzymatic inactivation of ribosomes,”Mol. Cell Bio., 10:6257-6263, 1990.
Frankel et al., “Selection and characterization of ricin toxin A-chain mutations in Saccharomyces cerevisiae,”Mol. Cell Bo., 9:415-420, 1989.
Hung et al., “Cloning and expression of three abrin A-chains and their mutants derived by site-specific mutagenesis inEscherichia coli,” Eur. J. Biochem., 219:83-87, 1994.
Berndt et al., “Mutagenic Analysis of a Receptor Contact Site of Interleukin-2: Preparation of an IL-2 Analog with Increased Potency,”Biochemistry, 33:6571-6577, 1994.
Obara et al., “Site-directed mutagenesis of the cell-binding domain of human fibronectin: separable, synergistic sites mediate adhesive function,”Cell, 53:649-657, 1988.
Baluna Roxana G.
Ghetie Victor F.
Smallshaw Joan Elizabeth
Vitetta Ellen S.
Board of Regents , The University of Texas System
Fulbright & Jaworski LLP
Kam Chih-Min
LandOfFree
Compositions and methods for modifying toxic effects of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for modifying toxic effects of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for modifying toxic effects of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4189040